Resmed Inc (RMD)
Health Care · Health Care Equipment · US stock · S&P 500 component
$238.97
▼ -3.26 (1.35%)
Fair valueFair
$298 +24.6% to fair value
$149fair band $208–$387$447
Day's range
$237.87 – $242.58
52-week range
$179.75 – $275.42
About Resmed Inc
ResMed makes devices and software that treat sleep apnea and other respiratory conditions, including masks, flow generators and cloud-connected monitoring tools. It sells to home medical equipment suppliers, hospitals and healthcare systems worldwide. Revenue comes from the initial sale of devices and from recurring replacement of masks and accessories, which helps connect its results to patient numbers and reimbursement policies.
Revenue at Resmed Inc was $5.7 billion across the last twelve months. Across three years, sales expanded by 10.2% a year. Operating profit was 33.4% of revenue. It earned a return on invested capital of 25%. Net debt to EBITDA is -0.3 times, which means the company holds more cash than debt. Shareholders receive a dividend yielding 1.0%. On the site's X-Ray Score, it rates 72 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $179.75 – $275.42Volume 2,546,700Daily, split-adjusted
Vitals
Market cap$34.9B
52-week range$179.75 – $275.42
Volume (last day)2,546,700
P/E (TTM)22.9
EBIT / EV yield5.5%
Free-cash-flow yield4.7%
Dividend yield1.0%
Revenue (TTM)$5.7B
Net income (TTM)$1.5B
Operating margin33.4%
Return on capital25.2%
Debt incl. leases$826M
Cash & securities$1.5B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$298model spread $282 – $317
Fair
+24.6% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $239
Undervalued < $208Fair $208 – $387Overvalued > $387
10-year DCF (market-scaled)
$343
Peer multiples
$282
Earnings power floor (not blended)
$110
Fundamentals-adjusted multiple
$268
Growth the price implies
10.5%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Strong business at a fair price
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
71/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield5.5%
Free-cash-flow yield4.7%
Fair value vs price1.2×
Growth
Strong
75/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)10.2%
EPS growth (3y)19.6%
Growth consistency100%
Profitability
Fair
69/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital25.2%
Operating margin33.4%
Gross profitability38.5%
Financial health
Strong
79/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA-0.3×
Interest coverNo interest cost
Dividends
Fair
67/100
Dividend is typical for its sector.
See the numbers →
Dividend yield1.0%
Dividends vs free cash flow22%
Dividend growth10.6%
Quarterly results: last 6 quarters
+7.9%
Mar '25
+10.2%
Jun '25
+9.1%
Sep '25
+11.0%
Dec '25
+10.8%
Mar '26
+8.6%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.5B.
Compare with peers
DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67 STE STERIS plc64Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 13 Good · ● 3 Average · ● 0 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldAverage
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverGood
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 75/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Operating income | $1.0B | $1.1B | $1.3B | $1.7B | $1.9B |
| Net income | $779M | $898M | $1.0B | $1.4B | $1.5B |
| Operating cash flow | $351M | $693M | $1.4B | $1.8B | $1.8B |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.4% |
| Free cash flow | $216M | $574M | $1.3B | $1.7B | $1.6B |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
| SMA 10 | 231.2 | Bullish |
| EMA 10 | 233.0 | Bullish |
| SMA 20 | 226.5 | Bullish |
| EMA 20 | 229.4 | Bullish |
| SMA 50 | 226.9 | Bullish |
| EMA 50 | 224.6 | Bullish |
| SMA 100 | 213.3 | Bullish |
| EMA 100 | 221.5 | Bullish |
| SMA 200 | 224.1 | Bullish |
| EMA 200 | 224.6 | Bullish |
Oscillators (daily)
| RSI (14) | 66.55 | Neutral |
| MACD (12, 26) | 3.67 | Bullish |
| Momentum (12) | 8.08 | Bullish |
| Stochastic %K (14) | 85.12 | Bearish |
| Williams %R (14) | -14.88 | Bearish |
| CCI (20) | 162.5 | Bearish |
Pivot points (classic, last session)
S3 232.3 | S2 235.1 | S1 237.0 | Pivot 239.8 | R1 241.7 | R2 244.5 | R3 246.5 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.46 USD
Yield on today's price
1.03%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 20 Aug 2026 | 0.6600 |
| 14 May 2026 | 0.6000 |
| 12 Feb 2026 | 0.6000 |
| 13 Nov 2025 | 0.6000 |
| 14 Aug 2025 | 0.6000 |
| 8 May 2025 | 0.5300 |
| 13 Feb 2025 | 0.5300 |
| 7 Nov 2024 | 0.5300 |
| 15 Aug 2024 | 0.5300 |
| 8 May 2024 | 0.4800 |
| 7 Feb 2024 | 0.4800 |
| 8 Nov 2023 | 0.4800 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
RMD SEC filings
1 Oct 2026
DEF 14ASEC EDGAR
Proxy statement
1 Sep 2026
8-KSEC EDGAR
Other events
17 Aug 2026
8-KSEC EDGAR
Change of auditor; Director or officer change
13 Aug 2026
10-KSEC EDGAR
Annual report
6 Aug 2026
8-KSEC EDGAR
Results of operations; Other events
7 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
1 May 2026
10-QSEC EDGAR
Quarterly report
30 Apr 2026
8-KSEC EDGAR
Director or officer change
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.